Imagine a world where medical treatments are tailored to your unique genetic profile, or where couples can predict the genetic traits of their future children. This is the vision of Nucleus Genomics, a startup that has just raised $14 million in Series A funding to bring personalized genetic testing to the masses.

The company, founded by 25-year-old Kian Sadeghi, uses saliva samples to sequence DNA and provide users with insights into their genetic predispositions for over 800 health conditions. With the cost of genome sequencing plummeting in recent years – from $1 million in 2007 to just $400 today – Nucleus is poised to make genetic testing a mainstream reality.

Sadeghi's vision is ambitious, but it's rooted in personal tragedy. He lost a cousin to a previously unknown genetic condition, which sparked his passion for making genetic testing accessible to all. His dedication has attracted high-profile investors like Alexis Ohanian's Seven Seven Six, Balaji Srinivasan, and SpaceX alum Achal Upadhyaya, who share his vision of a future where everyone has their genome on their smartphone.

Nucleus is not without controversy, however. Last year, the company launched Nucleus IQ, which claims to correlate users' genetics with markers for high intelligence. This move sparked debate among geneticists and ethicists, who questioned the accuracy and potential implications of such testing. Sadeghi has defended his approach, arguing that consumers should have access to as much information about their genetics as possible.

Founders Fund partner Delian Asparouhov, who has invested in Nucleus, shares Sadeghi's conviction. He believes that the average American should have the same level of information about their genetics as athletes do about their physical advantages. Asparouhov envisions a future where Nucleus's insights will become even more accurate, with users providing additional information about their physical traits to improve the model.

While some critics have raised concerns about the potential for eugenics, Asparouhov jokingly dismissed the idea, emphasizing the importance of empowering consumers with information about their genetics. As Nucleus continues to grow and refine its technology, it will be interesting to see how the company navigates these complex ethical issues.

For now, Nucleus is focused on expanding its user base and pushing the boundaries of what is possible with genetic testing. With its latest funding round, the company is one step closer to realizing its vision of a world where genetic testing is as routine as getting a check-up.